King to sell Pain Therapeutics' abuse-resistant oxycodone; terminated
Specialty pharma company King Pharmaceuticals paid $150mm in cash up front to Pain Therapeutics (PT) for a worldwide license (outside of Australia and New Zealand) to Remoxy, PT's abuse-resistant, long-acting oxycodone in Phase II trials for moderate-to-severe chronic pain. The companies also agreed to co-develop other abuse-resistant opioids including hydrocodone, hydromorphone (PTI202), and oxymorphone, all at the preclinical stage.
- Specialty Pharmaceuticals
- Controlled Release
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com